Pinealon 20mg

Pinealon 20 mg is a synthetic tripeptide research compound supplied by Grail Formula for scientific investigation and controlled laboratory experimentation involving peptide biochemistry, molecular neurobiology, cellular signalling, gene expression regulation and experimental peptide-associated cellular processes.

Pinealon is identified by the amino acid sequence Glu-Asp-Arg (EDR), consisting of glutamic acid, aspartic acid and arginine. Its short peptide structure has attracted scientific interest in experimental research involving peptide-cell interactions, molecular regulatory mechanisms and the relationship between small peptide sequences and intracellular biochemical pathways.

This preparation is supplied as a nominal 20 mg peptide research material with independent batch-specific analytical documentation from Liquilabs s.r.o., Czechia.

For research use only — not for human or veterinary use.

 

Product Overview

Pinealon is a synthetic tripeptide consisting of three amino acid residues arranged in the sequence glutamic acid, aspartic acid and arginine, commonly abbreviated as Glu-Asp-Arg or EDR.

Its relatively simple molecular structure makes Pinealon relevant to laboratory research involving short-chain peptides, molecular interactions, peptide-associated cellular signalling and experimental studies of gene expression regulation.

Grail Formula supplies Pinealon 20 mg as a nominal 20 mg peptide research preparation intended exclusively for controlled laboratory investigations and in vitro scientific experimentation.

Independent third-party analytical testing was conducted by Liquilabs s.r.o., Czechia. The Certificate of Analysis, published on 11 October 2026, identifies production batch GF-PINEA20-B242 and laboratory sample LYO-1004.

The analytical report documents a measured Pinealon assay content of 28.0 mg ± 0.1 mg and chromatographic purity of 96.6 % ± 0.5 percentage points.

The measured assay content exceeds the nominal 20 mg designation by 8.0 mg, representing a positive difference of 40.0 %. This substantial difference is disclosed separately from the chromatographic purity result.

The Certificate of Analysis also includes FTIR spectrum identification, retention time assessment, molecular ion mass identification, bacterial endotoxin testing, microbiological counts and elemental impurity screening.

These measurements provide batch-specific analytical information about the tested peptide preparation. They do not independently establish biological activity, experimental potency, specific cellular responses or suitability for administration.

 

Peptide Overview

Pinealon is a short synthetic peptide composed of three amino acids: glutamic acid, aspartic acid and arginine.

Its amino acid sequence is represented as Glu-Asp-Arg (EDR), placing it within the category of tripeptides investigated in peptide chemistry and experimental molecular biology.

Tripeptides are small molecular structures consisting of three amino acid residues connected by peptide bonds. Their relatively limited sequence length provides a useful framework for studying fundamental relationships between peptide composition, molecular properties and biochemical interactions.

Glutamic acid and aspartic acid contain acidic side chains, while arginine contains a basic guanidinium-containing side chain. The combination of these amino acids contributes to the physicochemical characteristics of the EDR sequence.

These molecular features are relevant to investigations involving peptide charge distribution, intermolecular interactions and the relationship between amino acid composition and experimental peptide behaviour.

Pinealon has been examined in experimental research involving cellular regulatory processes, molecular neurobiology and biochemical pathways associated with neuronal model systems.

Published experimental investigations have explored Pinealon-associated responses in relation to gene expression, cellular stress-associated signalling and molecular interactions involving genetic regulatory systems.

Such research contributes to broader scientific interest in how short peptide sequences may interact with cellular components under defined laboratory conditions.

However, the presence of a particular amino acid sequence does not independently establish biological activity or a specific molecular mechanism.

Experimental findings depend on the research model, peptide concentration, analytical methods and conditions used to evaluate molecular responses.

The Liquilabs Certificate of Analysis reports a molecular ion mass identification result of 418 Da ± 1 Da, supporting the analytical characterisation of the tested Pinealon preparation.

This molecular mass measurement is distinct from the quantitative assay result of 28.0 mg and the chromatographic purity of 96.6 %.

 

Historical Background and Scientific Context

Scientific investigation of short peptides developed through research into the molecular structure of proteins and the biochemical significance of amino acid sequences.

Early peptide chemistry established that amino acids can be connected through peptide bonds to form molecular chains with distinct structural and physicochemical properties.

As analytical chemistry and molecular biology advanced, researchers began investigating shorter peptide sequences as individual molecular entities rather than exclusively as components of larger proteins.

These investigations contributed to the development of peptide structure-function research and the study of interactions between small peptides and biological macromolecules.

Research involving short regulatory peptides expanded during the development of experimental peptide bioregulation studies.

Within this broader scientific field, investigators examined whether defined amino acid sequences could be associated with measurable changes in cellular biochemical processes under controlled experimental conditions.

Pinealon, represented by the EDR amino acid sequence, became a subject of experimental investigation in research involving molecular neurobiology and peptide-associated cellular regulation.

Scientific studies explored relationships between Pinealon and cellular processes associated with gene expression, molecular signalling and experimental neuronal systems.

Some investigations examined short peptide interactions with molecular components involved in genetic regulation, including experimental systems used to study DNA-associated processes.

These studies contributed to the broader scientific discussion surrounding possible interactions between short peptide sequences and intracellular regulatory mechanisms.

Research involving Pinealon has also been considered within the context of cellular stress-associated molecular responses and biochemical regulation in experimental neural models.

However, the findings reported in individual experimental systems do not establish a universally applicable molecular mechanism or guarantee reproducible biological activity across different peptide preparations.

Advances in synthetic peptide chemistry have enabled laboratories to produce defined short peptide sequences for analytical and molecular research.

Modern techniques such as ultra-high-performance liquid chromatography and mass spectrometry provide methods for evaluating peptide composition, molecular identity and quantitative content.

For short peptides such as Pinealon, analytical characterisation is particularly important because molecular identity, chromatographic purity and measured peptide quantity describe different properties of a research preparation.

Contemporary Pinealon research remains connected to broader scientific investigations involving peptide biochemistry, molecular neurobiology, experimental gene regulation and short peptide-associated cellular interactions.

 

Mechanistic Focus in Research

The principal mechanistic research interest surrounding Pinealon concerns its short amino acid sequence and the potential relationship between small peptide structures and cellular molecular regulatory processes.

Short peptide molecular interactions

Pinealon is investigated within the broader field of short peptide biochemistry, which examines how defined amino acid sequences interact with other molecular components.

Researchers may investigate relationships between peptide charge distribution, molecular conformation and interactions with proteins, nucleic acids or other biochemical structures.

The Glu-Asp-Arg sequence provides a research model for examining the physicochemical properties of small peptides containing both acidic and basic amino acid residues.

Gene expression-associated research

Experimental studies involving Pinealon have explored potential associations with gene expression regulation and intracellular molecular processes.

Gene expression is regulated through interconnected mechanisms involving transcription factors, chromatin organisation, regulatory proteins and nucleic acid-associated molecular interactions.

Laboratory investigations may use molecular techniques such as gene expression profiling and biochemical assays to examine experimentally observed changes in these systems.

Any specific regulatory activity must be established through dedicated experimental measurements and cannot be inferred from peptide identity alone.

Molecular neurobiology research

Pinealon has attracted scientific interest in experimental research involving neuronal cellular models and molecular processes associated with neural cell biology.

Investigations may examine intracellular signalling markers, gene expression patterns and biochemical responses under controlled laboratory conditions.

These research areas provide scientific context for studying short peptide-associated molecular interactions in experimental neuronal systems.

Cellular stress-associated pathways

Cellular stress research examines biochemical responses to experimentally induced changes in the intracellular environment.

Pinealon has been investigated in experimental contexts involving cellular stress-associated molecular regulation.

Researchers may evaluate biochemical markers, signalling intermediates and changes in cellular gene expression to characterise these responses.

Such investigations require appropriate controls and validated analytical methods to distinguish peptide-associated observations from unrelated experimental effects.

Peptide-nucleic acid interactions

Short peptide interactions with nucleic acids represent an area of molecular biology research involving the study of intermolecular recognition and physicochemical binding characteristics.

Experimental investigations may examine whether particular peptide sequences associate with DNA-related molecular structures under defined laboratory conditions.

The interpretation of such findings requires direct experimental evidence, as sequence composition alone does not establish specific nucleic acid binding or regulatory activity.

Analytical peptide characterisation

Pinealon is also relevant to analytical investigations involving synthetic peptide identity, chromatographic separation and molecular mass determination.

Techniques such as UHPLC and mass spectrometry provide information about the chemical characteristics of peptide research materials.

The supplied Liquilabs Certificate of Analysis documents chromatographic purity, quantitative assay content, FTIR spectrum identification, retention time assessment and molecular ion mass identification.

However, the report does not contain gene expression assays, neuronal functional measurements, peptide-nucleic acid binding studies or other biological activity testing.

Accordingly, the mechanistic research topics described above represent scientific research areas associated with Pinealon rather than experimentally confirmed functional properties of batch GF-PINEA20-B242.

 

Analytical Verification (COA)

Grail Formula provides independent batch-specific analytical documentation through testing conducted by Liquilabs s.r.o., Czechia.

The Certificate of Analysis for Pinealon 20 mg was published on 11 October 2026 and identifies production batch GF-PINEA20-B242, laboratory sample LYO-1004.

The 13-page report includes peptide assay results, chromatographic purity assessment, FTIR spectrum identification, retention time assessment, mass spectrometry, bacterial endotoxin testing, microbiological counts and elemental impurity screening.

Peptide assay and chromatographic purity

• Nominal product quantity: 20 mg
• Measured Pinealon assay content: 28.0 mg ± 0.1 mg
• Reported chromatographic purity: 96.6 % ± 0.5 percentage points
• Measured assay difference from nominal quantity: 8.0 mg above the labelled 20 mg
• Measured assay as a proportion of nominal quantity: 140.0 %
• Analytical screening designation: Peptide Screening 0.1% TFA

The measured assay content exceeds the nominal quantity by 40.0 %. This substantial positive difference is a batch-specific analytical finding and is disclosed independently of the chromatographic purity result.

The reported purity of 96.6 % describes the chromatographic composition under the applied analytical conditions. It does not mean that 96.6 % of the nominal 20 mg quantity was recovered.

The supporting analytical documentation includes UHPLC method specifications, calibration information and chromatographic records relating to peptide content and purity assessment.

Peptide identity assessment

• FTIR spectrum identification result: 998 ± 5, as reported
• Retention time identification result: 0.999 ± 0.005, as reported
• Molecular ion mass identification: 418 Da ± 1 Da
• Mass spectrometry identity assessment: MS deconvolution

The Certificate of Analysis includes chromatographic and mass spectrometric documentation supporting the analytical characterisation of the tested peptide.

The FTIR spectrum and retention time identification values are reproduced as reported. The summary does not provide separate explicit pass/fail interpretations for these measurements.

The molecular ion mass of 418 Da is an identity-related analytical result and is distinct from the measured peptide assay content expressed in milligrams.

Bacterial endotoxin assessment

• Bacterial endotoxin: below 0.001 EU/mg
• Laboratory acceptable range: 0–0.5 EU/mg
• Analytical reference: USP <85> / European Pharmacopoeia 2.6.14
• Method: Chromogenic bacterial endotoxin testing

The bacterial endotoxin result was reported as below 0.001 EU/mg, falling within the laboratory’s stated acceptable range.

This result indicates a concentration below the reported analytical threshold rather than confirmation of absolute absence of bacterial endotoxins.

The endotoxin result does not establish sterility, biological safety or suitability for administration.

Microbiological assessment

• Total aerobic microbial count: 0 CFU/g
• Total yeast and mould count: 0 CFU/g
• Reported aerobic microbial count range: 0–1000 CFU/g
• Reported yeast and mould count range: 0–100 CFU/g
• Analytical reference: USP <61> / European Pharmacopoeia 2.6.12
• Method: Plate-count testing

Both microbiological counts were reported as zero under the applied laboratory testing conditions.

These findings apply to the tested sample and do not demonstrate the absence of every possible microorganism.

Elemental impurity screening

Seven elemental impurities were evaluated using procedures referenced to USP <232> and European Pharmacopoeia 5.20 / 2.4.20.

• Arsenic: below 0.001 ppm
• Cadmium: below 0.001 ppm
• Mercury (listed as quicksilver): below 0.001 ppm
• Lead: below 0.001 ppm
• Nickel: below 0.001 ppm
• Vanadium: below 0.001 ppm
• Cobalt: below 0.001 ppm

All seven reported elemental impurity concentrations were below 0.001 ppm and within their respective laboratory acceptable ranges.

Results below the analytical reporting threshold indicate concentrations below that threshold rather than confirmation of absolute absence.

The complete Certificate of Analysis contains 13 pages of analytical findings and supporting documentation, including chromatographic records, mass spectrometric data, endotoxin determination information and microbiological testing methodology.

The reported findings relate exclusively to the tested sample and should not automatically be applied to unrelated production batches.

 

Research Applications

Pinealon is investigated in experimental peptide biochemistry, molecular neurobiology and research involving short peptide-associated cellular regulatory processes.

Its scientific relevance arises from its Glu-Asp-Arg sequence, relatively small molecular structure and investigated relationship with intracellular molecular regulation.

Potential areas of laboratory investigation include:

• Short peptide and tripeptide biochemistry research
• Experimental molecular neurobiology investigations
• Gene expression-associated molecular research
• Peptide-nucleic acid interaction studies
• Cellular stress-associated signalling investigations
• Peptide structure-function relationship research
• Experimental intracellular molecular regulation studies
• Comparative investigations involving short synthetic peptides
• Chromatographic purity and quantitative peptide analysis
• Mass spectrometric peptide identity assessment

These applications describe scientific research directions rather than demonstrated biological activity of the tested batch.

Experimental investigations require appropriate analytical controls, suitable reference materials and validated methods for evaluating peptide-associated biochemical responses.

Batch-specific Certificate of Analysis documentation can support laboratory recordkeeping and provide researchers with information about the measured characteristics of the preparation.

 

Grail Formula Quality

Grail Formula focuses on supplying laboratory research compounds supported by transparent product information and independently documented analytical findings.

For Pinealon 20 mg, Liquilabs testing provides batch-specific information concerning peptide assay content, chromatographic purity, analytical identity, bacterial endotoxin concentration, microbiological counts and selected elemental impurities.

The report documents a measured assay content of 28.0 mg against the nominal 20 mg quantity, chromatographic purity of 96.6 % and bacterial endotoxin concentration below 0.001 EU/mg.

These measurements are presented separately to maintain a clear distinction between peptide quantity, chromatographic composition and microbiological characteristics.

The substantial positive assay difference of 40.0 % is disclosed transparently as part of the batch-specific analytical profile.

Each result should be interpreted within the scope of the tested sample, the applied laboratory methodology and the reported measurement uncertainty.

 

When You Choose Grail Formula

Grail Formula provides Pinealon 20 mg with independent batch-specific analytical documentation from Liquilabs s.r.o., Czechia.

Researchers can review the Certificate of Analysis to examine the reported peptide assay, chromatographic purity, FTIR spectrum identification, retention time assessment, molecular ion mass, microbiological findings and elemental impurity results.

The report identifies the production batch, laboratory sample and publication date, supporting analytical traceability and laboratory documentation.

Grail Formula emphasises factual scientific descriptions, transparent reporting and clear distinctions between analytical measurements and biological properties that have not been established.

For laboratory research involving short synthetic peptides, molecular neurobiology and peptide-associated cellular regulatory processes, this documentation provides a reference for the measured characteristics of the tested Pinealon preparation.

 

Research Use Limitation

Used solely for in vitro experiments and cannot be:

• Used in clinical trials involving humans
• Administered to humans as part of an experiment or investigation
• Supplied to another party for human investigational use.

• Independently analysed by Liquilabs s.r.o. Czechia
• Pinealon synthetic tripeptide research compound with nominal 20 mg quantity
• Amino acid sequence: Glu-Asp-Arg (EDR)
• Chromatographic purity: 96.6 % ± 0.5 percentage points
• Assay content measured at 28.0 mg ± 0.1 mg
• Measured assay content 40.0 % above nominal quantity
• Identification evaluated by FTIR spectrum and retention time analysis
• FTIR spectrum identification result: 998 ± 5
• Retention time identification result: 0.999 ± 0.005
• Molecular ion mass identified at 418 Da ± 1 Da
• Bacterial endotoxin below 0.001 EU/mg
• Total aerobic microbial count: 0 CFU/g
• Total yeast and mould count: 0 CFU/g
• All seven reported elemental impurities below 0.001 ppm
• Batch number: GF-PINEA20-B242
• Laboratory sample identification: LYO-1004
• COA publication date: 11 October 2026
• Independent 13-page batch-specific Certificate of Analysis
• Investigated in short peptide biochemistry and molecular neurobiology research
• Relevant to controlled laboratory studies involving peptide-associated cellular regulation
• For research use only – not for human or veterinary use

For laboratory research only. Not intended for human consumption, injection, or cosmetic use.

This product is for research purposes only. Not for human use or diagnostic/therapeutic applications. Keep out of reach of children.